nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2014 | short review

Colorectal cancer: screening and some notes on the prevention

verfasst von: Paul Bergmeister, MD, Alois Hermann Lang, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

At the moment cancer screening is a hot topic which is widely discussed in scientific as well as in popular press. The expected benefits, improvement of prognosis and the reduction of mortality, must be weighed against potential harms, such as the risk of over-diagnosis, false-positive findings, and complications of invasive screening examinations. Screening for breast, cervical, and colorectal cancer has proven to be effective and is therefore recommended by major medical societies and international guidelines. Different tests for colorectal cancer screening are available. Besides established strategies using fecal occult blood test and colonoscopy new and potentially less invasive techniques are on the rise. Our aim is to discuss different strategies for colorectal cancer screening and to present the available screening tests. According to the World Health Organization prevention is the most cost-effective long-term strategy for the fight against cancer. Almost half of all cancer deaths are related to preventable causes. In general, life style modification and some dietary advices can be recommended, but the role of micronutrient supplements remains unclear. There is mounting evidence that some drugs such as nonsteroidal anti-inflammatory drugs, statins, or metformin may have a chemoprotective effect, but is there enough evidence to give general recommendations?

Vorheriger Artikel Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.PubMedCrossRef

Bundesanstalt Statistik Österreich. Statistik Austria: Dickdarm, Enddarm. Online 2013.

Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–33.PubMedCrossRef

Kinzler KW, Vogelstein B. The genetic basis of human cancer. 2nd ed. McGraw-Hill Professional; 2002. pp. 583–612.

Patai A V, Molnár B, Tulassay Z, Sipos F. Serrated pathway: alternative route to colorectal cancer. World J Gastroenterol. 2013;19:607–15.PubMedCrossRefPubMedCentral

Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Janssen-Heijnen MLG, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer. 2008;44:1463–75.PubMedCrossRef

Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med. 2009;361:1179–87.PubMedCrossRef

Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70.PubMedCrossRef

Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol. 2006;101:380–4.PubMedCrossRef

10.

Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–54.PubMedCrossRef

11.

Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JCIY, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–8.PubMedCrossRef

12.

Duffy MJ, van Rossum LGM, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2011;128:3–11.PubMedCrossRef

13.

Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.PubMedCrossRef

14.

Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95:230–6.PubMedCrossRef

15.

Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMedCrossRef

16.

Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. J Natl Cancer Inst. 2011;103:1310–22.PubMedCrossRef

17.

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010;102:1238–52.PubMedCrossRefPubMedCentral

18.

Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Inoue T. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey. Ann Nucl Med. 2014;28:212–9.PubMedCrossRef

19.

Negreanu L, Babiuc R, Bengus A, Sadagurschi R. PillCam Colon 2 capsule in patients unable or unwilling to undergo colonoscopy. World J Gastrointest Endosc. 2013;5:559–67.PubMedPubMedCentral

20.

Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.PubMedPubMedCentral

21.

Tóth K, Sipos F, Kalmár A, Patai A V, Wichmann B, Stoehr R, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE. 2012;7:e46000.PubMedCrossRefPubMedCentral

22.

Pox CP, Schmiegel W. [German S3-guideline colorectal carcinoma]. Dtsch Med Wochenschr. 2013;138:2545.PubMedCrossRef

23.

Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33:88–100.PubMedCrossRefPubMedCentral

24.

O’Morain C, Trinity CD, Lambert R. EU Guidelines for quality assurance in CRC screening and diagnosis. (International A for R on C, Rey J-F Institut AT). European Comission; 2010.

25.

Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.PubMedCrossRef

26.

Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7.PubMedCrossRefPubMedCentral

27.

Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164–78.PubMedCrossRefPubMedCentral

28.

Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin Use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852–61.PubMedCrossRef

29.

Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4:655–65.PubMedCrossRefPubMedCentral

30.

Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2:50–6.PubMedCrossRefPubMedCentral

31.

Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010;59:1572–85.PubMedCrossRef

32.

Lochhead P, Chan AT. Statins and colorectal cancer. Clin Gastroenterol Hepatol. 2013;11:109–18. (quiz e13–4).PubMedCrossRefPubMedCentral

33.

Tseng C-H. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012;167:409–16.PubMedCrossRef

34.

Thosani N, Thosani SN, Kumar S, Nugent Z, Jimenez C, Singh H, et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol. 2013;31:623–30.PubMedCrossRef

35.

Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012;12:118.PubMedCrossRefPubMedCentral

Titel: Colorectal cancer: screening and some notes on the prevention
verfasst von: Paul Bergmeister, MD
Alois Hermann Lang, MD
Publikationsdatum: 01.09.2014
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0154-8

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Clinicopathological profile of bilateral breast cancer at a tertiary cancer center in South India

Myelodysplastic syndromes (MDS)

Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: data at hand

The role of maintenance strategies in breast cancer

ASH 2013: constant progress: not only for B-cell neoplasms

Highlights of the American Society of Hematology Meeting 2013: hemostaseology